ronpopeil...I think the good thing about POZN is that they don't need to be bought out by anyone. The royalties they receive from treximet and eventually Vimovo will allow them to grow their PA ("safer aspirin") franchise and grow into a large very viable pharmaceutical company w/o the overhead of big pharma companies.
Message in reply to:
I agree with you on POZN $heff. I own a lot of that one too. Don't forget they are working on a third drug that is somewhat of a substitute for aspirin which is suppose to be easier on the stomach. If approved, that could easily be their biggest selling drug. No reason why this company can't have a $1 billion market cap with just Treximet and this new potentially FDA approved drug alone. Imo, they will be bought out, perhaps by Astra Zeneca.
Market Data 
Markets 
AI
